PubRank

David R Anderson

Author PubWeight™ 81.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003 8.55
2 Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 2003 8.33
3 Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003 7.15
4 Do workplace health promotion (wellness) programs work? J Occup Environ Med 2014 3.80
5 Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 2003 3.73
6 Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005 2.53
7 An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med 2006 1.78
8 A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005 1.75
9 A wake-up call for corporate America. J Occup Environ Med 2003 1.48
10 Review of the studies cited in the DataBase section of the American Journal of Health Promotion. Am J Health Promot 2004 1.38
11 A high C/O ratio and weak thermal inversion in the atmosphere of exoplanet WASP-12b. Nature 2010 1.34
12 A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther 2010 1.10
13 The role of incentive design, incentive value, communications strategy, and worksite culture on health risk assessment participation. Am J Health Promot 2009 1.08
14 Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood 2008 1.03
15 Linking Workplace Health Promotion Best Practices and Organizational Financial Performance: Tracking Market Performance of Companies With Highest Scores on the HERO Scorecard. J Occup Environ Med 2016 1.02
16 Catheter-associated thrombosis in patients with malignancy. J Clin Oncol 2009 1.00
17 Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2010 0.98
18 Inaccuracies in selected ion monitoring determination of isotope ratios obviated by profile acquisition: nucleotide 18O/16O measurements. Anal Biochem 2007 0.98
19 Effectiveness of a worksite telephone-based weight management program. Am J Health Promot 2011 0.95
20 Isotopologue distributions of peptide product ions by tandem mass spectrometry: quantitation of low levels of deuterium incorporation. Anal Biochem 2007 0.94
21 The relationship between health promotion program participation and medical costs: a dose response. J Occup Environ Med 2003 0.94
22 Hybrid procedure as an alternative to surgical palliation of high-risk infants with hypoplastic left heart syndrome and its variants. J Thorac Cardiovasc Surg 2010 0.93
23 Impact of financial incentives on behavior change program participation and risk reduction in worksite health promotion. Am J Health Promot 2012 0.93
24 Novel tetrahydro-beta-carboline-1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem Lett 2007 0.93
25 Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group. Transfusion 2007 0.92
26 Presenteeism according to healthy behaviors, physical health, and work environment. Popul Health Manag 2012 0.91
27 Self-rated job performance and absenteeism according to employee engagement, health behaviors, and physical health. J Occup Environ Med 2013 0.87
28 Exposure assessment of workers to airborne PCDD/Fs, PCBs and PAHs at an electric arc furnace steelmaking plant in the UK. Ann Occup Hyg 2008 0.87
29 Evaluation of a best-practice worksite wellness program in a small-employer setting using selected well-being indices. J Occup Environ Med 2011 0.86
30 The impact of worksite wellness in a small business setting. J Occup Environ Med 2011 0.85
31 Studies into the formation of dioxins in the sintering process used in the iron and steel industry. 1. Characterisation of isomer profiles in particulate and gaseous emissions. Chemosphere 2003 0.85
32 Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. Thromb Res 2008 0.84
33 Association between nine quality components and superior worksite health management program results. J Occup Environ Med 2008 0.84
34 Six-month exercise training program to treat post-thrombotic syndrome: a randomized controlled two-centre trial. CMAJ 2010 0.84
35 Effectiveness of compression stockings to prevent the post-thrombotic syndrome (the SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial. BMC Cardiovasc Disord 2007 0.83
36 Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay. J Med Chem 2012 0.83
37 Venous protocols, techniques, and interpretations of the upper and lower extremities. Radiol Clin North Am 2004 0.82
38 Discovery of indazoles as inhibitors of Tpl2 kinase. Bioorg Med Chem Lett 2011 0.82
39 A review of the knowledge base on healthy worksite culture. J Occup Environ Med 2012 0.81
40 Aqueous versus non-aqueous salt delivery strategies to enhance oral bioavailability of a mitogen-activated protein kinase-activated protein kinase (MK-2) inhibitor in rats. J Pharm Sci 2009 0.81
41 Endoluminal repair of aneurysms associated with coarctation. Ann Thorac Surg 2003 0.80
42 Psychological impact of thrombophilia testing in asymptomatic family members. Thromb Res 2011 0.80
43 PCDD/F and "Dioxin-like" PCB emissions from iron ore sintering plants in the UK. Chemosphere 2006 0.80
44 The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study. Can J Cardiol 2007 0.80
45 Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode. Bioorg Med Chem Lett 2010 0.80
46 Guidelines for the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med Rev 2007 0.79
47 Building program participation: strategies for recruitment and retention in worksite health promotion programs. Am J Health Promot 2004 0.79
48 Strategies for strengthening the evidence base for employee health promotion programs. Am J Health Promot 2011 0.79
49 Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dog. Toxicol Pathol 2010 0.78
50 Inter-observer reliability of measures to assess the post-thrombotic syndrome. Thromb Haemost 2008 0.78
51 An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. J Clin Pharmacol 2014 0.77
52 Financial impact of population health management programs: reevaluating the literature. Popul Health Manag 2012 0.77
53 The diagnosis of deep venous thrombosis and pulmonary embolism in medical-surgical intensive care unit patients. J Crit Care 2005 0.77
54 Finding common ground in the use of financial incentives for employee health management: a call for a progress-based approach. Am J Health Promot 2011 0.77
55 Association between changes in health risk status and changes in future health care costs: a multiemployer study. J Occup Environ Med 2012 0.77
56 Development and validation of a method for analysis of "dioxin-like" PCBs in environmental samples from the steel industry. Chemosphere 2004 0.76
57 A pilot study to assess the feasibility of a multicenter cluster randomized trial for the management of asymptomatic persons with a thrombophilia. J Genet Couns 2009 0.75
58 Speaking with one voice on worksite wellness: the American Cancer Society, the American Diabetes Association, and the American Heart Association. Am J Health Promot 2011 0.75
59 Aspirin versus low-molecular-weight heparin after total hip arthroplasty. Ann Intern Med 2013 0.75
60 CRAFT: Facilitating clinical trial execution quality. AMIA Annu Symp Proc 2007 0.75
61 Use of a normal impairment factor in quantifying avoidable productivity loss because of poor health. J Occup Environ Med 2009 0.75
62 Using PCDD/F congener patterns to determine the source of elevated TEQ concentrations in cows milk: a case study. Chemosphere 2002 0.75
63 Twenty-Two Health Promotion Pioneers. Am J Health Promot 2015 0.75
64 Intrapericardial teratoma presenting in fetal life: intrauterine diagnosis and neonatal management. Congenit Heart Dis 2008 0.75
65 The predictive validity of the HERO Scorecard in determining future health care cost and risk trends. J Occup Environ Med 2014 0.75
66 Assessment of exposure to PCDD/F, PCB, and PAH at a basic oxygen Steelmaking (BOS) and an iron ore sintering plant in the UK. Ann Occup Hyg 2011 0.75
67 Reflections on developments in health promotion in the past quarter century from founding members of the American Journal of Health Promotion Editorial Board. Am J Health Promot 2011 0.75
68 Dose assessment from chronic exposure to industrial NORM in iron ore processing. J Radiol Prot 2017 0.75
69 Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. J Med Chem 2017 0.75
70 Influence of Incentive Design and Organizational Characteristics on Wellness Participation and Health Outcomes. J Occup Environ Med 2020 0.75
71 Removal of vapour phase PCDD/Fs in electric arc furnace steelmaking emissions by sorption using plastics. Chemosphere 2008 0.75
72 Influence of warfarin on symptoms of fatigue: findings of a randomized trial. Ann Pharmacother 2005 0.75